BioAtla (BCAB) Company Report

BioAtla, Inc. is registering securities under a Form S-3 registration statement, which became effective on January 17, 2023.
The company is offering up to $7,500,000 of common stock through Pre-Paid Advance Agreements with YA II PN, Ltd., Anson Investments Master Fund LP, and Anson East Master Fund LP.
An additional offering of up to $15,000,000 of common stock and 243,428 Commitment Shares is being made through a Standby Equity Purchase Agreement with Yorkville (YA II PN, Ltd.).
As of November 21, 2025, BioAtla has 58,792,088 shares of Common Stock outstanding.
The company acknowledges that the issuance of these Common Shares could cause dilution to existing shareholders.

Nov 21, 2025, 11:15 AM

BioAtla Reports Q3 2025 Financials, Advances Strategic Transaction, and Secures FDA Alignment for OSV Phase 3 Trial

BCAB

Earnings

New Projects/Investments

M&A

BioAtla reported a net loss of $15.8 million for the third quarter ended September 30, 2025, compared to a net loss of $10.6 million in the same quarter of 2024, and had $8.3 million in cash and cash equivalents as of September 30, 2025.
The company is in advanced stages to finalize a strategic transaction with a potential partner by year-end.
FDA alignment was achieved on the Phase 3 OSV registrational trial design for second-line plus oropharyngeal squamous cell carcinoma (OPSCC), with estimated worldwide peak sales of OSV projected at approximately $800 million in this indication alone.
A $2 million milestone payment was received in October 2025 from Context Therapeutics under a license agreement for the dual CAB, NECTIN-4 TCE program.
Preliminary data for the dual CAB, EpCAM, T-cell engager (BA3182) showed a manageable safety profile and encouraging signs of tumor reductions, with a key clinical trial readout expected in the first half of 2026.

Nov 13, 2025, 9:30 PM

BioAtla Announces Positive Clinical Data for Mecbotamab Vedotin in Sarcoma

BCAB

New Projects/Investments

BioAtla, Inc. (Nasdaq: BCAB) announced clinical data for its AXL-targeting antibody-drug conjugate (ADC), Mecbotamab Vedotin (Mec-V), at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.
In a Phase 2 clinical trial, Mec-V demonstrated a median overall survival (OS) of 21.5 months in 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma, compared to approximately 12 months with approved agents.
The 12-month OS rate for Mec-V was 73%, which is higher than the approximately 50% historically reported for approved agents in similar populations.
The safety profile of Mec-V, both as monotherapy and in combination with an anti-PD-1 antibody, was manageable and consistent, with generally low-grade, transient adverse events.